Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

BACKGROUND: Tofacitinib is the first oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA). We compared the effectiveness and safety of tofacitinib, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor inhibitors (TNFi), and non-TNF biologics in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Machado, Marina Amaral de Ávila, Moura, Cristiano Soares de, Guerra, Steve Ferreira, Curtis, Jeffrey R., Abrahamowicz, Michal, Bernatsky, Sasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865387/
https://www.ncbi.nlm.nih.gov/pubmed/29566769
http://dx.doi.org/10.1186/s13075-018-1539-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865387/
https://www.ncbi.nlm.nih.gov/pubmed/29566769
http://dx.doi.org/10.1186/s13075-018-1539-6

Ejemplares similares